Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 Diabetes
- First Online:
- Cite this article as:
- Sreenan, S., Andersen, M., Thorsted, B.L. et al. Diabetes Ther (2014) 5: 447. doi:10.1007/s13300-014-0075-x
- 843 Downloads
Severe hypoglycemic events (SHEs) are associated with significant morbidity, mortality and costs. However, the more common non-severe hypoglycemic events (NSHEs) are less well explored. We investigated the association between reported frequency of NSHEs and SHEs among patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) in the PREDICTIVE study.
PREDICTIVE was a global, prospective, observational study. Patients with T1DM (n = 7,420) or T2DM (n = 12,981), starting treatment with insulin detemir, reported the number of NSHEs and SHEs experienced during the 4 weeks prior to baseline and follow-up visits (mean 14.4 weeks). Logistic regression was used to determine the odds ratio (OR) of experiencing ≥1 SHE, in patients having 1–4 or ≥5 NSHEs, versus those having 0 NSHEs, while controlling for baseline covariates.
Hypoglycemia rates were lower at follow-up than baseline. At baseline 59.2% (T1DM) and 18.8% (T2DM) reported any hypoglycemia and at follow-up 39.5% (T1DM) and 8.6% (T2DM). There was a significant (P < 0.0001) increase in the odds of ≥1 SHEs with increasing frequency of NSHEs in T1DM and T2DM, for both crude and adjusted estimates. At baseline, in T1DM, ORs for ≥1 SHE were 1.92 and 2.13 for 1–4 and ≥5 NSHEs, respectively; the corresponding ORs in T2DM were 10.83 and 15.36, respectively. At follow-up, the ORs for ≥1 SHE were 2.01 and 3.20 (T1DM) and 18.99 and 24.29 (T2DM) for 1–4 and ≥5 NSHEs, respectively.
A statistically significant association between NSHE and SHE frequency was found in T1DM and T2DM. These data provide a clear rationale for the reduction of hypoglycemic events, regardless of severity, while striving for optimal glycemic control.
KeywordsDiabetes mellitus Hypoglycemia Insulin detemir Non-severe hypoglycemia Observational studies Severe hypoglycemia
Hypoglycemic events are of major clinical importance, adversely affecting health, quality of life, adherence to therapy and workplace productivity [1, 2, 3, 4, 5, 6]. They represent a significant clinical concern and source of distress in patients with both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) [7, 8, 9, 10, 11], both for insulin users as well as for patients using only oral antidiabetic drugs (OADs) [12, 13, 14, 15]. Hypoglycemic events or fear of such events has been identified as the major treatment-limiting factors in titrating insulin to optimal glycemic targets in T2DM [16, 17]. A recent meta-analysis of 13 randomized trials suggested that the harm associated with severe hypoglycemic events (SHEs) could even negate the benefit of intensive glucose reduction . Emergency hospitalizations arising from SHEs represent a considerable economic cost to patients and insurers [19, 20, 21]. Despite the clinical consequences of hypoglycemia and the burden it causes to patients and health-care providers, in one large (n = 3,827) European survey, 65% of people with T1DM and 50–59% of people with T2DM who experienced a non-severe hypoglycemic event (NSHE) rarely or never informed their physician about hypoglycemia; additionally, among all responders, 17% of those with T1DM and 21–28% with T2DM reported not being asked about hypoglycemia by their physician during routine appointments . Clinically, there may be an impression that the lower frequency of hypoglycemia in T2DM means that it is of lesser clinical importance in that type of diabetes; such an interpretation, however, may not adequately characterize the impact of hypoglycemia in T2DM [8, 9, 23].
Given this background, understanding the constellation of factors predisposing to hypoglycemia, and SHEs in particular, is of considerable clinical importance . One of the most consistently reported risk factors for SHEs is a history of prior SHEs . For example, in one observational study of 267 patients with insulin-treated diabetes, statistically significant predictors of hypoglycemia in T1DM included a history of previous hypoglycemia (P = 0.006) and co-prescribing of any oral medication (P = 0.048) . For T2DM, a history of previous hypoglycemia (P = 0.0001) and duration of insulin treatment (P = 0.014) were significant. NSHEs, for which third-party assistance is not required, occur far more commonly than SHEs; however, the clinical and economic relevance of such events may be underappreciated, especially in T2DM. In particular, there is a lack of data reflecting the potential association between NSHEs and SHEs.
The aim of this study was to report data on the co-occurrence of NSHEs and SHEs (without inferring a causal relationship between the two) and, using a regression model, to determine which covariates influence the likelihood of experiencing a SHE.
PREDICTIVE was a global, prospective, open-label, observational study of more than 20,000 patients with T1DM or T2DM intended to evaluate the safety and efficacy of insulin detemir in routine clinical practice; details of the study design and primary results have been published [25, 26, 27]. This secondary analysis reports data on the frequency of NSHEs and SHEs, along with their co-occurrence, in insulin-treated patients with T1DM (n = 7,420) or T2DM (n = 12,981) from 11 countries (Austria, Czech Republic, Denmark, Finland, Germany, Ireland, Israel, Netherlands, Sweden, Turkey, and the UK). We selected PREDICTIVE (Clinicaltrials.gov #NCT00659295) for this analysis because it was unique in the systematic way in which NSHEs were recorded and the trial enrolled sufficient numbers of patients to allow analysis of SHEs in people with T2DM. As an observational study, we also believed PREDICTIVE offered the advantage of reflecting real-world practice. The analysis in this article does not involve any new studies of human or animal subjects performed by any of the authors.
Patients entering this study were prescribed insulin detemir (100 U/ml formulation) by their physician as part of routine clinical care and followed up for a mean period of 14.4 weeks. Patients currently using insulin detemir were ineligible. 75% of patients with T1DM were using a basal-bolus regimen at baseline, compared with 25% of those with T2DM. A further 31% of patients with T2DM were using insulin plus OADs and 27% used OADs without insulin. Neutral protamine Hagedorn insulin was the most commonly used basal insulin prior to entering the study (63% T1DM, 66% T2DM), followed by insulin glargine (34% T1DM, 29% T2DM). All decisions about insulin dose, frequency of dosing and other treatments were at the discretion of the patient’s physician.
Patients reported the number of NSHEs and SHEs experienced during the 4 weeks prior to baseline and during a 4-week period prior to the end of their follow-up visit. SHEs were defined as an episode with symptoms of neuroglycopenia, in which the patient was unable to treat himself/herself and third-party intervention was needed, and where the patient had one of the following characteristics: (i) blood glucose <2.8 mmol/L (<50 mg/dL) or (ii) reversal of symptoms after food intake, glucagon or intravenous glucose administration. Confirmed hypoglycemic events where third-party assistance was not required were classified as NSHEs. SHEs were categorized into 0 versus ≥1 in frequency, and NSHEs were classified as 0, 1–4, and ≥5 in frequency, during the two reporting periods.
Demographic variables and baseline diabetes characteristics were summarized with descriptive statistics. Hypoglycemic events were analyzed by severity and frequency (NSHEs: 0, 1–4, ≥5 events; SHEs: 0 and ≥1 event). The primary end point of this study was the association between NSHEs and SHEs at baseline and between NSHEs and SHEs at follow-up. Cross-tabulations and the Chi-square test were used to test for statistically significant associations between frequencies of NSHE and SHE, for T1DM and T2DM. Unadjusted and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for experiencing ≥1 SHEs, in patients having 1–4 and ≥5 NSHEs versus those with 0 NSHEs, were estimated using multivariate logistic regression so that the effect of potential covariates could be taken into account. Covariates for adjusted ORs included age, body mass index (BMI), duration of diabetes, baseline glycosylated hemoglobin (HbA1c) and gender, which are all potential confounders of the relationship between NSHEs and SHEs. Data were stratified by type of diabetes for all analyses. All analyses were performed using SAS® 9.3 Software (SAS Institute Inc., Cary, NC, USA).
Baseline characteristics of participants in the PREDICTIVE study
Patients with type 1 diabetes N = 7,420
Patients with type 2 diabetes N = 12,981
Female (n, %)
Male (n, %)
Missing (n, %)
41.4 ± 16.8
60.6 ± 10.8
≤55 years (n, %)
>55–65 years (n, %)
>65 years (n, %)
Missing (n, %)
Diabetes duration, years
16.4 ± 12.5
11.2 ± 7.5
0–5 years (n, %)
>5–10 years (n, %)
>10–20 years (n, %)
>20 years (n, %)
Missing (n, %)
Body mass index, kg/m2
25.2 ± 4.5
30.9 ± 5.9
≤25 kg/m2 (n, %)
>25–30 kg/m2 (n, %)
>30–35 kg/m2 (n, %)
>35 kg/m2 (n, %)
Missing (n, %)
Baseline HbA1c, %
8.2 ± 1.6
8.5 ± 1.6
≤7.5 (n, %)
>7.5–8.0 (n, %)
>8.0–9.0 (n, %)
>9.0 (n, %)
Missing (n, %)
Frequency of Hypoglycemic Events
The proportion of patients providing data concerning the frequency of hypoglycemic events was high (>90%) at baseline (n = 7,399/7,420 and n = 12,966/12,981, for T1DM and T2DM, respectively) and at follow-up (n = 6,837/7,420 and 12,368/12,981, for T1DM and T2DM, respectively). Hypoglycemic episodes per patient year have been reported previously . As might be expected, both during the 4-week reporting periods at baseline and at follow-up, a greater proportion of patients with T1DM reported a hypoglycemic event (baseline: T1DM, 4,380/7,399, 59.2%; T2DM 2,443/12,966, 18.8%; follow-up: T1DM, 2,702/6,837, 39.5%; T2DM, 1,062/12,368, 8.6%). As these data show, the frequency of all hypoglycemic events decreased in both T1DM and T2DM from baseline to follow-up.
Association Between NSHEs and SHEs at Baseline
At baseline, there was a statistically significant association between the frequency of NSHEs and SHEs, both for patients with T1DM (P < 0.0001) and for those with T2DM (P < 0.0001). For patients with T1DM, those who experienced NSHEs had more than twice the odds of experiencing ≥1 SHE, compared with those who experienced 0 NSHEs: unadjusted ORs [95% CIs] were 2.07 [1.72; 2.49] for 1–4 NSHEs, and 2.31 [1.90; 2.82] for ≥5 NSHE. By comparison, for patients with T2DM, the odds of experiencing ≥1 SHE were >10–15 times greater for those who experienced an NSHE, compared to those who did not experience an NSHE in the 4 weeks prior to the study (OR = 11.09 [8.91; 13.81] for 1–4 NSHEs, and OR = 15.36 [11.47; 20.57] for ≥5 NSHEs).
Association Between NSHEs and SHEs at Follow-up
At follow-up, after a mean of 14.4 weeks of therapy using insulin detemir, there was a statistically significant association between the frequency of NSHEs and the occurrence of SHEs, both for patients with T1DM (P < 0.0001) and those with T2DM (P < 0.0001). For patients with T1DM, those who experienced NSHEs had >2 times the odds of also experiencing a SHE, compared with those who experienced 0 NSHEs (OR = 2.21 [1.51; 3.22] for 1–4 NSHEs vs. 0 NSHEs, and OR = 3.78 [2.47; 5.80] for ≥5 NSHE vs. 0 NSHEs [values are unadjusted ORs and 95% CIs]). For patients with T2DM, the odds of experiencing a SHE were >15–20 times greater for those who experienced an NSHE, compared to those who did not experience an NSHE (OR = 16.65 (8.66; 32.02) for 1–4 NSHEs vs. 0 NSHEs, and OR = 21.74 [7.17; 65.91] for ≥5 NSHE vs. 0 NSHEs).
Finally, 9% of T1DM and 3% of T2DM patients who experienced a SHE at baseline also experienced an event at follow-up. In contrast 1% (T1DM) and 0.2% (T2DM) experienced a SHE at follow-up without experiencing a SHE at baseline.
These observational data, from a large cohort of patients with T1DM or T2DM in 11 countries (PREDICTIVE study) using insulin detemir in a setting of routine care provide confirmation of a strong association between the occurrence of NSHEs and SHEs. Importantly, the odds of experiencing ≥1 SHE increased with increasing frequency of NSHEs (i.e., 0, 1–4 and ≥5 events), both at baseline and at follow-up. This supports the notion that NSHEs could predispose to SHEs, a concept that is supported by the relationship between NSHEs and SHEs being maintained despite adjustment for potential confounders, both in patients with T1DM and T2DM.
As previously reported for the PREDICTIVE study, the absolute frequency of NSHEs and SHEs all decreased significantly from baseline (P < 0.0001) . Despite this decrease in frequency of hypoglycemic events following treatment with insulin detemir, the association between the frequency of NSHEs and SHEs in this secondary analysis remained statistically significant. Because of the very high level of reporting (>90%) and collection of data over a comparatively short period of time (4-week periods), reporting fatigue should have been minimized. Although the odds of experiencing a SHE in subjects with NSHEs were actually higher at follow-up, it is likely that with fewer patients experiencing hypoglycemia, events were concentrated within the most vulnerable individuals, with the association between NSHEs and SHEs thereby becoming even stronger. Interestingly, the advantage of T2DM with respect to having lower frequency of SHEs (compared to T1DM) was tempered once any NSHE was reported.
An interesting finding was that the effect of increasing frequency of NSHEs on odds of having ≥1 SHEs was much greater in T2DM than in T1DM, being at least fivefold greater at baseline and more than eightfold greater at follow-up. The odds of ≥1 SHE were increased from 10- to 25-fold for patients with T2DM who reported NSHEs, whereas the odds of ≥1 SHE increased only about 2- to 3-fold for patients with T1DM who reported NSHEs (Figs. 2, 3). This further highlights the relevance of hypoglycemia in T2DM, which, as others have noted , may be underappreciated and highlights the need to adopt strategies directed toward the reduction of both severe and non-severe hypoglycemia in patients with both T1DM and T2DM. Furthermore, our analysis indicates that overweight people with T2DM (BMI >35 kg/m2) seemed to have a lower frequency of both NSHE and SHE which can be explained by increasing insulin resistance.
Potential mechanisms that may account for the association between NSHEs and SHEs observed in our analysis may relate to the effect of recurrent symptomatic hypoglycemia with respect to blunted subsequent counter-regulatory hormone secretion . Our data may also reflect an extension of observations from the Action In Diabetes And Vascular Disease: Preterax And Diamicron Modified Release Controlled Evaluation (ADVANCE; ClinicalTrials.gov #NCT00145925) study , suggesting a clustering of hypoglycemia in susceptible individuals.
This study supports other data evaluating the relevance of non-severe hypoglycemia. Indeed, NSHEs have a significant detrimental effect on patients’ quality of life, adherence to prescribed insulin doses and workplace productivity . This was recently demonstrated from a survey of people with diabetes in the USA, UK, Germany and France, where over a 1-month period, mean losses in workplace productivity were estimated to range from $US15.26–93.47 in relation to each NSHE. The cost of hospital treatment of a SHE is considerably greater. In one study of 639 patients in Germany, Spain and the UK, costs per SHE averaged $US304–693 per event .
Data concerning the incidence of either NSHEs or SHEs in this study must be interpreted with the understanding that hypoglycemic events were only reported during a 4-week period at baseline and a 4-week period at the end of the study. Due to the study design, it is not possible to determine whether increased frequency of NSHEs precedes the occurrence of SHEs and whether a causal relationship exists. It is thus possible that our observations represent an indication bias translating into a clustering of hypoglycemia episodes in people predisposed to those events. To address such a consideration, it would be interesting to investigate the temporal relationship between NSHEs and SHEs. It is also possible that unrecorded clinical or socio-demographic factors that influence the risk of overall hypoglycemia could potentially bias the results of this analysis. However, it should be noted that in this study, we did measure and control for factors that have been reported elsewhere as important confounding variables . Another potential confounding factor in this analysis is the influence of reporting bias, since the data rely on patient-reported hypoglycemic events. Self-monitored blood glucose values were not available for any patients with NSHEs. Thus, it is possible that some of these patients may have had blood glucose <2.8 mmol/L. However, in this study, the key distinguishing factor between SHEs and NSHEs was the requirement for assistance by a third party. Finally, at follow-up all patients were treated with insulin detemir which could influence the generalizability of the association found in this study.
The number of SHEs was too small to allow stratification and analysis according to the baseline regimen in T2DM. However, the diversity of baseline regimens is reflective of routine clinical practice, thus perhaps increasing the generalizability of our results. Logistic regression (dichotomous outcome and hence ORs) were used instead of Poisson regression (counts) for several reasons. Very few patients had >1 SHE, and the time period was the same for all patients and comparatively short; therefore a Poisson model was not appropriate and results would have been very similar to modeling a dichotomous outcome. The total number of SHEs may not have been determined precisely. For these reasons, we focused our analysis on whether or not ≥1 SHE occurred and did not attempt to model the number of SHEs. Since there is a considerable degree of variability in the definition of hypoglycemia, combined with the observation that the definition of SHEs versus NSHEs is not always explicit or clear between studies , future studies with a consistent definition of hypoglycemia are required to further explain the relationship between NSHEs and SHEs.
NSHEs appear to be an important factor consistently and independently associated with the risk of SHEs among patients with both T1DM and T2DM. The magnitude of this risk association was more pronounced for patients with T2DM, highlighting the importance of non-severe hypoglycemia both in patients with T1DM and T2DM. Regardless of whether NSHEs are a prelude to, or simply a marker for, SHEs (which in the worst case may be fatal), it is essential that physicians obtain an accurate account of their patients’ hypoglycemic experience during consultations. These results thus provide both clinical and economic rationale for making every effort to reduce the frequency of hypoglycemic events, regardless of severity, in patients with T1DM or T2DM.
This study and the article processing charges were sponsored by Novo Nordisk and registered at clinicaltrials.gov. All named authors meet the ICMJE criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole and have given final approval to the version to be published. The authors are grateful to Gary Patronek and Mark Nelson of Watermeadow Medical (supported by Novo Nordisk) for writing assistance and submission assistance.
Conflict of interest
Prof. Seamus Sreenan has acted as advisory board member and speaker for Novartis, Novo Nordisk, Eli Lilly and Company, Merck Sharpe & Dohme, Bristol-Myers Squibb and sanofi-aventis; as a speaker for Glaxo Smith Kline and AstraZeneca; and has received grants from Novo Nordisk, Eli Lilly and Company, Sanofi-Aventis, AstraZeneca and Bristol-Myers Squibb. Marc Andersen is Consultant for Novo Nordisk A/S. Brian L. Thorsted is an employee and shareholder of Novo Nordisk A/S. Michael Lyng Wolden is an employee and shareholder of Novo Nordisk A/S. Marc Evans has received research awards, honoraria and consultancy fees from Novo Nordisk, Sanofi-Aventis, Merck Sharpe & Dohme, Novartis, Eli Lilly and Company, and Takeda. All authors contributed to design, conduct/data collection, analysis and interpretation of data and to the writing and final approval of this article.
Compliance with ethics guidelines
The analysis in this article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.